Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal
growth of the vessels beneath the retina. Ranibizumab (Lucentis) is a new drug that inhibits
the growth of new vessels and has recently been approved by FDA for treating this condition.
This study is carried out to evaluate the changes in retinal function after an injection of
ranibizumab.